Cargando…

Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients

Purpose: The reported data of elderly ESCC are rather limited and there is a lack of information to guide treatment decisions for elderly patients with esophageal cancer. This study aims to identify the efficacy and factors for optimal treatment approaches for elderly esophageal squamous cell carcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Lina, Zhou, Yongchun, Pan, Haitao, Yin, Yutian, Chai, Guangjin, Mu, Yunfeng, Xiao, Feng, Lin, Steven H., Shi, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665040/
https://www.ncbi.nlm.nih.gov/pubmed/29158796
http://dx.doi.org/10.7150/jca.20835
_version_ 1783275107649585152
author Zhao, Lina
Zhou, Yongchun
Pan, Haitao
Yin, Yutian
Chai, Guangjin
Mu, Yunfeng
Xiao, Feng
Lin, Steven H.
Shi, Mei
author_facet Zhao, Lina
Zhou, Yongchun
Pan, Haitao
Yin, Yutian
Chai, Guangjin
Mu, Yunfeng
Xiao, Feng
Lin, Steven H.
Shi, Mei
author_sort Zhao, Lina
collection PubMed
description Purpose: The reported data of elderly ESCC are rather limited and there is a lack of information to guide treatment decisions for elderly patients with esophageal cancer. This study aims to identify the efficacy and factors for optimal treatment approaches for elderly esophageal squamous cell carcinoma (ESCC) treated with radiotherapy (RT) alone or concurrent chemoradiation (CCRT). Methods: This study included 184 I-III elderly ESCC patients aged ≥70 years treated by oral single agent CCRT (sCCRT) or double agents CCRT (dCCRT) or RT alone at a single institution in China. RT was delivered with Intensity Modulated Irradiation Therapy (IMRT) or Volumetric-Modulated Arc Therapy (VMAT). Sequential or simultaneous integrated boost (SIB) approach was applied for GTV dose escalation. Toxicities were evaluated by criteria of Radiation Therapy Oncology Group. Statistical analyses were performed on survival and failure patterns. Results: At a median follow-up time of 15.5 months, the 2- and 3-year estimated overall survival (OS) were 43.5% and 35.2%, respectively. T and N stage, GTV dose (cutoff value 56Gy), simultaneous integrated boost (SIB) technique and CCRT were significant predictors for the outcomes. sCCRT was significantly associated with higher OS, LRFS, and DFS when compared with RT alone and no difference was observed between sCCRT and dCCRT. 44% patients experienced treatment failure, among whom 65.4% developed local failure. 81.3% local failure occurred in GTV and 70.6% regional failures occurred out of radiation field. dCCRT was the only independent prediction factor for grade ≥ 2 neutropenia and gastrointestinal reactions compared with sCCRT and RT alone. No significant difference of toxicities was observed between sCCRT and RT alone. Conclusions: Our results demonstrated that CCRT in elderly patients had significant survival benefit compared to RT alone, especially using Single oral agent. sCCRT had less toxicities compared to dCCRT, and the toxicity was similar to RT alone. GTV dose ≥ 56 Gy and SIB technique were optimal approaches for radiotherapy.
format Online
Article
Text
id pubmed-5665040
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-56650402017-11-20 Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients Zhao, Lina Zhou, Yongchun Pan, Haitao Yin, Yutian Chai, Guangjin Mu, Yunfeng Xiao, Feng Lin, Steven H. Shi, Mei J Cancer Research Paper Purpose: The reported data of elderly ESCC are rather limited and there is a lack of information to guide treatment decisions for elderly patients with esophageal cancer. This study aims to identify the efficacy and factors for optimal treatment approaches for elderly esophageal squamous cell carcinoma (ESCC) treated with radiotherapy (RT) alone or concurrent chemoradiation (CCRT). Methods: This study included 184 I-III elderly ESCC patients aged ≥70 years treated by oral single agent CCRT (sCCRT) or double agents CCRT (dCCRT) or RT alone at a single institution in China. RT was delivered with Intensity Modulated Irradiation Therapy (IMRT) or Volumetric-Modulated Arc Therapy (VMAT). Sequential or simultaneous integrated boost (SIB) approach was applied for GTV dose escalation. Toxicities were evaluated by criteria of Radiation Therapy Oncology Group. Statistical analyses were performed on survival and failure patterns. Results: At a median follow-up time of 15.5 months, the 2- and 3-year estimated overall survival (OS) were 43.5% and 35.2%, respectively. T and N stage, GTV dose (cutoff value 56Gy), simultaneous integrated boost (SIB) technique and CCRT were significant predictors for the outcomes. sCCRT was significantly associated with higher OS, LRFS, and DFS when compared with RT alone and no difference was observed between sCCRT and dCCRT. 44% patients experienced treatment failure, among whom 65.4% developed local failure. 81.3% local failure occurred in GTV and 70.6% regional failures occurred out of radiation field. dCCRT was the only independent prediction factor for grade ≥ 2 neutropenia and gastrointestinal reactions compared with sCCRT and RT alone. No significant difference of toxicities was observed between sCCRT and RT alone. Conclusions: Our results demonstrated that CCRT in elderly patients had significant survival benefit compared to RT alone, especially using Single oral agent. sCCRT had less toxicities compared to dCCRT, and the toxicity was similar to RT alone. GTV dose ≥ 56 Gy and SIB technique were optimal approaches for radiotherapy. Ivyspring International Publisher 2017-09-15 /pmc/articles/PMC5665040/ /pubmed/29158796 http://dx.doi.org/10.7150/jca.20835 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Zhao, Lina
Zhou, Yongchun
Pan, Haitao
Yin, Yutian
Chai, Guangjin
Mu, Yunfeng
Xiao, Feng
Lin, Steven H.
Shi, Mei
Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients
title Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients
title_full Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients
title_fullStr Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients
title_full_unstemmed Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients
title_short Radiotherapy Alone or Concurrent Chemoradiation for Esophageal Squamous Cell Carcinoma in Elderly Patients
title_sort radiotherapy alone or concurrent chemoradiation for esophageal squamous cell carcinoma in elderly patients
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5665040/
https://www.ncbi.nlm.nih.gov/pubmed/29158796
http://dx.doi.org/10.7150/jca.20835
work_keys_str_mv AT zhaolina radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients
AT zhouyongchun radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients
AT panhaitao radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients
AT yinyutian radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients
AT chaiguangjin radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients
AT muyunfeng radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients
AT xiaofeng radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients
AT linstevenh radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients
AT shimei radiotherapyaloneorconcurrentchemoradiationforesophagealsquamouscellcarcinomainelderlypatients